JP2019504030A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504030A5
JP2019504030A5 JP2018532747A JP2018532747A JP2019504030A5 JP 2019504030 A5 JP2019504030 A5 JP 2019504030A5 JP 2018532747 A JP2018532747 A JP 2018532747A JP 2018532747 A JP2018532747 A JP 2018532747A JP 2019504030 A5 JP2019504030 A5 JP 2019504030A5
Authority
JP
Japan
Prior art keywords
zika virus
virus vaccine
vaccine
seq
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504030A (ja
JP6949027B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/082664 external-priority patent/WO2017109225A1/en
Publication of JP2019504030A publication Critical patent/JP2019504030A/ja
Publication of JP2019504030A5 publication Critical patent/JP2019504030A5/ja
Application granted granted Critical
Publication of JP6949027B2 publication Critical patent/JP6949027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532747A 2015-12-23 2016-12-23 ジカウイルスワクチン Active JP6949027B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP15202585.4 2015-12-23
EP16161068.8 2016-03-18
EP16161068 2016-03-18
EP16176025 2016-06-23
EP16176049.1 2016-06-23
EP16176049 2016-06-23
EP16176025.1 2016-06-23
EP16182845 2016-08-04
EP16182845.4 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (3)

Publication Number Publication Date
JP2019504030A JP2019504030A (ja) 2019-02-14
JP2019504030A5 true JP2019504030A5 (https=) 2019-12-26
JP6949027B2 JP6949027B2 (ja) 2021-10-20

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532747A Active JP6949027B2 (ja) 2015-12-23 2016-12-23 ジカウイルスワクチン

Country Status (19)

Country Link
US (14) US11331382B2 (https=)
EP (9) EP3393508B9 (https=)
JP (1) JP6949027B2 (https=)
KR (1) KR102950500B1 (https=)
CN (2) CN108697785B (https=)
AU (1) AU2016375338B2 (https=)
BR (1) BR112018012873A2 (https=)
CA (1) CA3009278A1 (https=)
DK (1) DK3393510T5 (https=)
ES (4) ES2973267T3 (https=)
FI (1) FI3393510T3 (https=)
HR (1) HRP20230273T1 (https=)
HU (1) HUE061679T2 (https=)
LT (1) LT3393510T (https=)
MX (1) MX2018007627A (https=)
PL (1) PL3393510T3 (https=)
SG (1) SG11201805120YA (https=)
SI (1) SI3393510T1 (https=)
WO (6) WO2017109224A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
EP3322441A4 (en) * 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
ES2973267T3 (es) 2015-12-23 2024-06-19 Valneva Se Purificación de virus
BR112018077540A2 (pt) * 2016-07-08 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスchikv-delta 5nsp3を含む医薬組成物を製造する方法
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
MX2020005554A (es) * 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CN107904215B (zh) * 2017-12-27 2021-07-27 华农(肇庆)生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
CN119488586A (zh) * 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
JP2022523044A (ja) * 2019-01-22 2022-04-21 ブルーバード バイオ, インコーポレイテッド ウイルスベクターを製造するための方法及びシステム
BR112021019845A2 (pt) * 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
AU2020327602A1 (en) 2019-08-09 2022-01-27 Valneva Se Chikungunya vaccine formulations
EP4010016A1 (en) 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine
EP4028511A1 (en) * 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
US12521429B2 (en) 2020-02-05 2026-01-13 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング CpGアジュバント化SARS-CoV-2ウイルスワクチン
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
AU2021232062A1 (en) 2020-03-06 2022-09-29 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン,インコーポレイテッド ジカウイルス特異的抗体の検出方法
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4476329A1 (en) * 2022-02-09 2024-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
DK1025209T3 (da) * 1997-08-28 2007-06-25 Cheil Jedang Corp Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine
AU774045B2 (en) * 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
BRPI0910686A2 (pt) * 2008-04-21 2015-09-29 Tissue Regeneration Therapeutics Inc células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3322441A4 (en) 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
ES2973267T3 (es) 2015-12-23 2024-06-19 Valneva Se Purificación de virus
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスchikv-delta 5nsp3を含む医薬組成物を製造する方法

Similar Documents

Publication Publication Date Title
JP2019504030A5 (https=)
US11207397B2 (en) Virus purification
JP5129805B2 (ja) 細胞培養物から精製水疱性口内炎ウイルスを単離するための精製プロセス
TW202203967A (zh) 不活化SARS—CoV—2病毒疫苗
JPWO2000020565A1 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
US20240293531A1 (en) Inactivated sars-cov-2 virus vaccine
HK40103263A (en) Virus purification
HK40106064A (en) Virus purification
HK1261326A1 (en) Virus purification
HK1261326B (en) Virus purification
HK1261562A1 (en) Virus purification
HK1261562B (en) Virus purification
AU2007221746A1 (en) Improvements in virus production